Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
29 Maio 2023 - 9:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a clinical-stage biotechnology company developing novel
LAG-3 immunotherapies for cancer and autoimmune disease, today
announces it has entered into an agreement with Charles River under
which Charles River will conduct a GLP toxicology study for IMP761,
Immutep's proprietary preclinical candidate for autoimmune
diseases. IMP761 is a first-in-class LAG-3 agonist antibody that
aims to address the underlying cause of many autoimmune diseases,
namely the overactivation of self-antigen-specific memory T cells
expressing LAG-3.
Preclinical toxicology studies are an essential
part of drug development as they help to evaluate the potential
safety and toxicity of a drug candidate before it is tested in
humans. With its well-established expertise assisting companies in
early-stage drug development, Charles River is the partner of
choice to help progress our IMP761 program through this key stage
of IND-enabling studies.
“Immutep is continuing its pioneering work in
the LAG-3 immunotherapy landscape, as we advance IMP761, the
world’s first LAG-3 agonist antibody, towards the clinic in the
first half of next year. With its novel ability to enhance the
signalling of the LAG-3 inhibitory receptor and down-regulate
auto-reactive memory T cells at the centre of many autoimmune
diseases, we believe IMP761 has the potential to change how immune
disorders are treated. We are pleased to be working with an
established global company like Charles River for this next
important step of our pre-clinical development,” stated Immutep’s
Chief Scientific Officer, Frédéric Triebel, M.D., Ph.D.
IMP761’s agonistic activation of LAG-3 is
relevant for many diseases, including the Th1-driven autoimmune
disease setting. In a pre-clinical oligoarticular juvenile
idiopathic arthritis model IMP761 decreased secretion of nearly all
measured cytokines, and several key cytokines (IL-10, IL-12, IL-1β,
IL-4, and IL-6) reached the level of statistical-significance
(p < 0.01). These results were published
in Pediatric Research in May 2021.
The GLP (Good Laboratory Practice) toxicology
results and other preclinical studies will be an essential part of
the Company’s clinical trial application for IMP761.
About IMP761IMP761, a
first-in-class immunosuppressive LAG-3 agonist antibody, has the
potential to address the root cause of many autoimmune diseases by
specifically silencing autoimmune memory T cells that accumulate at
disease sites. These T cells express LAG-3 as an “exhaustion
marker” after being repeatedly stimulated with dominant
self-peptides. As published in the Journal of
Immunology in January 2020, encouraging pre-clinical results
were achieved with IMP761 leading to significant inhibition of
inflammatory T cell infiltration. Additional pre-clinical findings
published in Pediatric Research in May 2021 show
IMP761 led to large decreases in effector T cell cytokine secretion
in a juvenile arthritis model.
About
ImmutepImmutep is a clinical stage biotechnology
company developing novel LAG-3 immunotherapy for cancer and
autoimmune disease. We are pioneers in the understanding and
advancement of therapeutics related to Lymphocyte Activation Gene-3
(LAG-3), and our diversified product portfolio harnesses its unique
ability to stimulate or suppress the immune response. Immutep is
dedicated to leveraging its expertise to bring innovative treatment
options to patients in need and to maximise value for shareholders.
For more information, please visit www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S. Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024